Company Information & Market Analysis GlaxoSmithKline PLC (NYSE:GSK)‚ formed through the merger of British drug makers Glaxo Wellcome and SmithKline Beecham in December 2000‚ ranks as the world’s second largest pharmaceutical company. GSK group engaged in the creation‚ discovery‚ development‚ manufacture and marketing of pharmaceutical and consumer health-related products. GlaxoSmithKline supply one quarter of the world ’s vaccines and by the end of February 2008 GSK had 24 vaccines in clinical
Premium Pharmaceutical industry
history. This project looked at GlaxoSmithKline in Dungarvan‚ Co. Waterford. GSK has been manufacturing in Dungarvan since 1981 and has two manufacturing sites there. The first is the Oral care facility which was set up in 1981 and the second is the over the counter medicine site which was set up in 1987. Many of the company’s flagship brands are produced in Dungarvan including Panadol‚ Polygrip and NiQuitn. According to the GSK Website “Products produced in Dungarvan are exported to more than 70 countries
Premium
Glaxosmithkline is a global leader in the market of pharmaceutical goods and services‚ currently holding 7% of market share in this field. Formerly Glaxo Wellcome plc‚ the firm merged in December 2000 with Smithkline Beecham‚ a leading manufacturer of medical and consumer healthcare goods. ‚ however there is much dispute over the motives behind the merger and what Glaxo Wellcome sought to gain through the collaboration. This is of particular concern as following the merger‚ many shareholders and
Premium Pharmaceutical industry
important that we generate more growth with less risk." GSK needs to find new sources of growth at a time when governments around the world are reforming healthcare and cutting spending. It is also outsourcing more research to partners to reduce risk. Its long-running collaboration with the US company‚ Theravance which is responsible for one of GSK ’s most promising new drugs‚ the asthma treatment Relovair‚ which is now in late-stage development. GSK recently upped its stake in Theravance to 19% and this
Premium Clinical trial Strategic management Pharmacology
Financial Analysis of GlaxoSmithKline Liquidity Ratio 1. Current ratio Year | 2007 | 2008 | 2009 | 2010 | 2011 | Current Ratio: | 4.64 times | 2.96 times | 3.11 times | 2.59 times | 2.05 times | Interpretation: In 2011‚ the company’s current assets were 2.05 times the current liabilities. The current ratio has been decreasing significantly over the years and this clearly indicates that the current ratio is not in a good shape. In 2011‚ although the current assets have increased
Premium Balance sheet Asset Inventory
COMPANY OVERVIEW GlaxoSmithKline (GSK) is one of the world’s leading research-based pharmaceutical and healthcare companies. The company is engaged in the discovery‚ development‚ manufacturing and marketing of pharmaceutical and consumer health-related products. The company primarily operates in 120 countries and its products are sold in more than 150 countries. GSK is headquartered in Brentford‚ the UK and employed 99‚913 people as of December 31‚ 2009. The company recorded revenues of £28‚368
Premium
1. INTEPRETATONS OF FINANCIAL RATIOS A. GlaxoSmithKline at a glance. “GlaxoSmithKline (GSK) is a global healthcare company specialized in the discovery‚ development‚ manufacturing and marketing pharmaceutical and consumer health-related products. GSK has operations in about 114 countries‚ with products being sold in over 150 countries”. A. Evaluation of profitability ratios. For the evaluation of the profitability ratio over five-year period we will analyse the
Premium Financial ratios Financial ratio
art European air hub at Leipzig/Halle Airport in Germany. In this document I will be covering both a PEST and SWOT analysis of DHL as a company. PEST Analysis of DHL‚ the PEST itself looks into the Political‚ Economic‚ Social and Technological Factors of a company and its marketing environment. Focusing on the internal environment‚ micro-environment and the macro-environment. Using a PEST analysis should always be considered when entering a new market‚ Launching a new product or service‚ considering
Premium Management United Parcel Service Retailing
PEST analysis PEST analysis stands for "Political‚ Economic‚ Social‚ and Technological analysis" and describes a framework of macroenvironmental factors used in the environmental scanning component of strategic management. It is a part of the external analysis when conducting a strategic analysis or doing market research and gives a certain overview of the different macroenvironmental factors that the company has to take into consideration. It is a useful strategic tool for understanding market
Free PEST analysis Strategic management Management
EC229 Economics of Strategy Introduction 1. GlaxoSmithKline (GSK) is a global healthcare company specialized in the research‚ development‚ manufacturing and marketing of pharmaceutical and consumer health-related products. The company has operations in 120 countries‚ with products being sold in over 150 countries. (Description) 2. As a dominant player in the pharmaceutical industry‚ GSK operates in an oligopolistic market. It is highly cash generative‚ with increased sales growth and shareholder
Premium Costs Economics Oligopoly